Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment

Reuters

2025/12/01

<a href="https://laohu8.com/S/PPCB">Propanc Biopharma</a> Unveils Patents for Novel Cancer and Fibrosis Treatment

Propanc Biopharma Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588739107"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588739107\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588739107?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588739107","market":"us","top_or_hot":-1,"title":"Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Unveils Patents for Novel Cancer and Fibrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPropanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-01 22:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Unveils Patents for Novel Cancer and Fibrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL694P6g:1","article_id":"2588739107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588739107","pubTimestamp":1764597835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Propanc Biopharma Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PPCB":"Propanc Biopharma, Inc."},"translate_title":"Propanc Biopharma公布新型癌症和纤维化治疗专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PPCB":0.9},"content_text":"Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment\n    \n\nPropanc Biopharma Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}